{
  "id": 11147913,
  "title": "Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates",
  "url": "https://urgent.news/2026/10/01/samsung-bioepis-and-teva-expand-strategic-partnership-to-advance-up",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T08:32:14.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/samsung-bioepis-and-teva-expand-strategic-partnership-to-advance-up-to-six-potential-biosimilar-candidates"
  },
  "original_language": "en",
  "account": null,
  "summary": "The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories The partnership brings together…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BusinessKorea",
        "title": "Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates",
        "url": "https://urgent.news/2026/10/01/samsung-bioepis-and-teva-expand-strategic-partnership-to-advance-up-11154150",
        "published": "2026-10-01T09:20:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}